

Semi-annual Syndicated Oncology Patient Chart Audits

OncoMAX, a product of Metrika, an IQVIA business, is a suite of targeted syndicated oncology patient chart audits in key cancers

Monitor your dynamic market share, and determine the patient demographics that drive prescription, with the most current and representative oncology patient chart audit in Canada.

Why OncoMAX?

Moderate-to-high treaters


- Online patient chart audit conducted with up to 50 moderate-to-high treaters of the cancer of interest

Nationally distributed

- Robust, nationally distributed sample with representation from academic & community cancer centers

Up-to-date and relevant

- Detailed information on current patients started on first-, second-, third- or fourth-line therapy in the past 6 months
- Fieldwork conducted within a month and reports delivered the following month, 2 times a year, to accurately reflect current trends in the market



Subscriptions are available for the following cancers:

- Metastatic Breast Cancer (mBC)
- Advanced Prostate Cancer (aPCa)
- Metastatic Non-small Cell Lung Cancer (mNSCLC)
- Metastatic Colorectal Cancer (mCRC)
- Multiple Myeloma (MMY)
- Metastatic Renal Cell Carcinoma (mRCC)
- Chronic Myeloid Leukemia (CML)
- Metastatic Melanoma (mM)

Are you looking for another cancer type? Metrika is the top provider of customized oncology patient chart audits.

SYNDICATED PATIENT CHART AUDIT GATHERS THE FOLLOWING METRICS

- 1 Patient demographics (age, gender, date of diagnosis)
- 2 Current Treatment and treatment history
- 3 Funding for current therapy
- 4 Timelines from diagnosis to current treatment (duration of prior lines of therapy)
- 5 Biomarker tests conducted and test results
- 6 ECOG status prior to initiating each line of therapy
- 7 Concomitant conditions, metastases location
- 8 Other relevant cancer-specific information
- 9 Reasons for stopping or switching prior therapies
- 10 Intended next therapy upon disease progression

Contact IQVIA today to learn more about syndicated and custom reports available for other tumor types.

CONTACT US

canadainfo@iqvia.com
iqvia.com/canada